Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, M20 4BX, United Kingdom.
Curr Med Chem. 2020;27(29):4789-4805. doi: 10.2174/0929867327666200422143847.
Hepatocellular carcinoma (HCC) is a frequent and increasing cause of cancerrelated deaths worldwide. Reversing this trend is complicated by the varied aetiological factors leading to liver cirrhosis resulting in molecular genetic and clinical heterogeneity, combined with frequent presentation at advanced stage. Large-scale genomic studies have identified alterations in key signalling pathways for HCC development and progression, but these findings have not yet directly influenced patient management in the clinical setting. Despite these translational challenges, a small number of anti-angiogenic systemic therapy agents have succeeded in recent randomized trials enriching the repertoire of available treatments for advanced HCC. In addition, the early promise of immune checkpoint inhibition is now on the cusp of delivering changes to standard systemic therapy algorithms. This review focuses on recent translational and clinical developments that have advanced. current practice and explores the challenges encountered in attempting to improve the outcomes and experience of patients diagnosed with advanced HCC.
肝细胞癌 (HCC) 是全球癌症相关死亡的常见且日益增加的原因。这种趋势难以扭转，原因是导致肝硬化的病因因素多种多样，导致分子遗传和临床异质性，再加上经常处于晚期。大规模基因组研究已经确定了 HCC 发生和发展的关键信号通路的改变，但这些发现尚未直接影响临床环境中的患者管理。尽管存在这些转化方面的挑战，但少数抗血管生成的系统治疗药物在最近的随机试验中取得了成功，丰富了晚期 HCC 可用治疗方法的组合。此外，免疫检查点抑制的早期前景现在即将改变标准系统治疗算法。这篇综述重点介绍了最近在推进当前实践方面取得的转化和临床进展，并探讨了在试图改善晚期 HCC 患者的预后和体验方面所遇到的挑战。
